CHARACTERIZATION OF THE PARATHYROID CELL CA2+ RECEPTOR

Information

  • Research Project
  • 3507480
  • ApplicationId
    3507480
  • Core Project Number
    R44DK043636
  • Full Project Number
    5R44DK043636-03
  • Serial Number
    43636
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/30/1990 - 33 years ago
  • Project End Date
    4/30/1994 - 30 years ago
  • Program Officer Name
  • Budget Start Date
    5/1/1993 - 31 years ago
  • Budget End Date
    4/30/1994 - 30 years ago
  • Fiscal Year
    1993
  • Support Year
    3
  • Suffix
  • Award Notice Date
    5/26/1993 - 31 years ago

CHARACTERIZATION OF THE PARATHYROID CELL CA2+ RECEPTOR

DESCRIPTION (Adapted from applicant's abstract):Recent studies demonstrate the presence of a calcium receptor protein on parathyroid cell that enables these cells to detect and respond to changes in the concentration of extracellular calcium. Drugs that act on this receptor to mimic the effects of extracellular calcium would offer a novel therapeutic approach to the treatment of hyperparathyroidism. In Phase I studies, it was shown that certain organic compounds were able to act on the calcium receptor and inhibit parathyroid hormone secretion. In Phase II, the proposal is to establish a data base that defines the structural features of compounds that contribute to activity on the calcium receptor. This will be obtained by limited structure-activity studies on compounds shown to be effective in Phase I studies and by testing of selected natural product compounds. It is also proposed to clone the calcium receptor cDNA in order to obtain structural information about the receptor and to create transfected cell lines necessary for high-throughput screening of natural product libraries. The proposed studies, which constitute the first description of the pharmacology and structure of the calcium receptor, will provide the technologies enabling a drug development program aimed at the discovery and design of drug candidates for the treatment of hyperparathyroidism.

IC Name
NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
  • Activity
    R44
  • Administering IC
    DK
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    847
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    SSS
  • Study Section Name
  • Organization Name
    NPS PHARMACEUTICALS, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    BEDMINSTER
  • Organization State
    NJ
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    07921
  • Organization District
    UNITED STATES